title: Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
abstract: BACKGROUND
  Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen.
  
  
  OBJECTIVE
  To compare the safety/efficacy of 3-drug vs 4-drug regimens for initial treatment of HIV-1 infection.
  
  
  METHODS
  The AIDS Clinical Trials Group (ACTG) A5095 study, a randomized, double-blind, placebo-controlled study with enrollment and follow-up conducted from March 22, 2001, to March 1, 2005, and enrolling treatment-naive, HIV-1-infected patients with HIV-1 RNA levels of 400 copies/mL or greater from US clinical trials units of the ACTG.
  
  
  METHODS
  Zidovudine/lamivudine plus efavirenz (3-drug regimen) vs zidovudine/lamivudine/abacavir plus efavirenz (4-drug regimen).
  
  
  METHODS
  Time to virologic failure (defined as time to first of 2 successive HIV-1 RNA levels > or =200 copies/mL at or after week 16), CD4 cell count changes, and grade 3 or 4 adverse events. HIV-1 RNA data were intent-to-treat, regardless of treatment changes.
  
  
  RESULTS
  Seven hundred sixty-five patients with a baseline mean HIV-1 RNA level of 4.86 log10 (72,444) copies/mL and CD4 cell count of 240 cells/mm3 were randomized. After a median 3-year follow-up, 99 (26%) of 382 and 94 (25%) of 383 patients receiving the 3-drug and 4-drug regimens, respectively, reached protocol-defined virologic failure; time to virologic failure was not significantly different (hazard ratio, 0.95; 97.5% confidence interval, 0.69-1.33; P = .73). In planned subgroup analyses, increased risk for virologic failure was seen in non-Hispanic black patients (adjusted hazard ratio, 1.66; 95% confidence interval, 1.18-2.34; P = .003). At 3 years, the HIV-1 RNA level was less than 200 copies/mL in 152 (90%) of 169 and 143 (92%) of 156 patients receiving the 3-drug and 4-drug regimens, respectively (P = .59), and less than 50 copies/mL in 144 (85%) of 169 and 137 (88%) of 156 patients (P = .39). CD4 cell count increases and grade 3 or 4 adverse events were not significantly different.
  
  
  CONCLUSIONS
  In treatment-naive patients, there were no significant differences between the 3-drug and 4-drug antiretroviral regimens; overall, at least approximately 80% of patients had HIV-1 RNA levels less than 50 copies/mL through 3 years. These results support current guidelines recommending 2 nucleosides plus efavirenz for initial treatment of HIV-1 infection; adding abacavir as a fourth drug provided no additional benefit.
  
  
  BACKGROUND
  clinicaltrials.gov Identifier: NCT00013520.
authors.affiliation: Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA. rgulick@med.cornell.edu
authors.forename: Roy M
authors.initials: RM
authors.lastname: Gulick
authors.forename: Heather J
authors.initials: HJ
authors.lastname: Ribaudo
authors.forename: Cecilia M
authors.initials: CM
authors.lastname: Shikuma
authors.forename: Christina
authors.initials: C
authors.lastname: Lalama
authors.forename: Bruce R
authors.initials: BR
authors.lastname: Schackman
authors.forename: William A
authors.initials: WA
authors.lastname: Meyer
authors.forename: Edward P
authors.initials: EP
authors.lastname: Acosta
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Schouten
authors.forename: Kathleen E
authors.initials: KE
authors.lastname: Squires
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Pilcher
authors.forename: Robert L
authors.initials: RL
authors.lastname: Murphy
authors.forename: Susan L
authors.initials: SL
authors.lastname: Koletar
authors.forename: Margrit
authors.initials: M
authors.lastname: Carlson
authors.forename: Richard C
authors.initials: RC
authors.lastname: Reichman
authors.forename: Barbara
authors.initials: B
authors.lastname: Bastow
authors.forename: Karin L
authors.initials: KL
authors.lastname: Klingman
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Kuritzkes
mesh_terms: D000328:Adult; D000368:Aged; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000008:administration & dosage; D012333:RNA, Messenger / Q000097:blood; D019562:Viral Load; D015215:Zidovudine / Q000008:administration & dosage; D000099227:Abacavir
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D019259:Lamivudine; D010078:Oxazines; D012333:RNA, Messenger; D015215:Zidovudine; D000099227:Abacavir; C098320:efavirenz